SG&A at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's SG&A?
- BioMarin Pharmaceuticals (BMRN) reported SG&A of $258.29M in Q1 2026.
- How has BioMarin Pharmaceuticals's SG&A changed year-over-year?
- BioMarin Pharmaceuticals's SG&A increased by 25.3% year-over-year, from $206.12M to $258.29M.
- What is the long-term trend for BioMarin Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's SG&A has grown at a 11.0% compound annual growth rate (CAGR), from $759.38M to $1.15B.
- What does SG&A mean?
- The overhead costs of running the business and selling products.
- How do you interpret SG&A?
- An increase often reflects investment in commercial launches, while excessive growth relative to revenue may indicate operational inefficiency.
- How does SG&A compare across companies?
- Benchmark against peers based on the stage of product commercialization and market size.